博騰股份(300363.SZ):第三季度淨利預增30%-40%
格隆匯10月11日丨博騰股份(300363.SZ)披露2021年前三季度業績預告,預計2021年1-9月實現歸屬於上市公司股東的淨利潤3.47億元-3.70億元,同比增長45%–55%;預計2021年7-9月實現歸屬於上市公司股東的淨利潤1.40億元-1.51億元,同比增長30%-40%。
2021年前三季度,公司不斷拓展和豐富產品管線,持續提升技術能力、產品交付能力和獲單能力,預計實現營業收入較去年同期增長35%-40%。同時,隨着公司產能利用率和運營效率的進一步提高,以及產品結構的優化,公司盈利能力水平不斷提升。
2021年第三季度,公司製劑CDMO和基因細胞治療CDMO兩大新業務板塊仍處於虧損階段,合計減少公司合併報表歸屬於上市公司股東的淨利潤約2500萬元。2021年前三季度,公司兩大新業務板塊合計減少公司合併報表歸屬於上市公司股東的淨利潤約7100萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.